The suitable cancers may include:
Non-Small Cell Lung Cancer (NSCLC), Colorectal adenocarcinoma, Mammary Analogue of Secretory Carcinoma (MASC) of the salivary gland, Squamous cell head and neck cancer, Spitzoid melanoma, Gastrontestinal Stromal Tumor (GIST), Cholangiocarcinoma, Soft tissue sarcoma, Inflammatory Myofibroblastic Tumor (IMT), Soft tissue fibrosarcoma (pediatric), Soft tissue fibrosarcoma (pediatric), Soft tissue schwannoma (pediatric), Soft tissue hemangioma (pediatric), Soft tissue solitary fibrous tumor (pediatric), Infantile (congenital) fibrosarcoma, Glioblastoma Multiforme (GBM), Low grade glioma, Pediatric non-brainstem high grade glioma, Papillary thyroid, and Secretory breast carcinoma, Pigmented spindle cell nevus/Spitz nevus, Bladder cancer, Breast cancer, Rectal adenocarcinoma, Renal carcinoma, Renal medullary carcinoma, Thyroid cancer (anaplastic) and Thyroid cancer (medullary).
TPX-0005 (Repotrectinib) could be used for treating resistant patients developed from the treatment(s) of:
- TRK inhibitors: larotrectinib, entrectinib, LOXO-195 and others;
- ROS1 inhibitors: crizotinib, lorlatinib, entrectinib, ceritinib, and others;
- ALK inhibitors: crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, ensartinib, entrectinib, and others.